10-Q: FONAR Q1 Earnings Decline Amid Rising Costs, Take-Private Bid

FONAR Corporation reported a significant drop in Q1 net income and operating income, driven by increased costs, while a take-private proposal and government shutdown add uncertainty.

Summary

• Net income attributable to FONAR decreased by 27.8% to $2.264 million for the three months ended September 30, 2025, compared to $3.135 million in the prior year period.
• Consolidated net income fell by 33.25% to $2.670 million from $4.000 million year-over-year.
• Operating income decreased by 30.7% to $3.194 million for the quarter, down from $4.606 million in the same period last year.
• Total revenues increased by 4.3% to $26.043 million, up from $24.960 million in the prior year, primarily due to increases in management and other fees, product sales, and service fees.
• Total costs and expenses rose by 12.2% to $22.849 million, compared to $20.354 million in the previous year, outpacing revenue growth.
• A non-binding proposal was received on July 7, 2025, from a group led by the CEO and COO to acquire all outstanding common stock not currently owned by the group, aiming to take the company private.
• The aggregate number of MRI scans performed by owned and managed sites increased to 55,106 in Q1 FY26 from 53,054 in Q1 FY25, attributed to IT system improvements, increased shift coverage, and equipment expansions, as well as recovery from hurricane-related closures in the prior year.
• A material weakness in internal controls over financial reporting related to information technology general controls (logical access management) was identified and continues to exist, with remediation efforts ongoing.

Sentiment

Score: 3

Explanation: The company experienced a significant decline in profitability (operating income down 30.7%, net income down 27.8%) despite a modest revenue increase, primarily due to rising costs. The ongoing take-private proposal creates uncertainty, and the company faces substantial external risks including government shutdown impacts, reduced reimbursement rates, inflation, and cybersecurity vulnerabilities. The identified material weakness in internal controls further adds to concerns, indicating a challenging operational and financial environment.

Positives

• Total revenues increased by 4.3% to $26.043 million for the quarter ended September 30, 2025, compared to $24.960 million in the prior year.
• Patient fee revenue saw a slight increase to $7.572 million from $7.487 million year-over-year.
• Product sales significantly increased to $316,000 from $120,000 in the comparable period.
• Service and repair fees grew to $2.182 million from $1.992 million.
• Management and other fees increased to $12.941 million from $12.329 million.
• The aggregate number of scans performed by owned and managed sites increased to 55,106 in Q1 FY26 from 53,054 in Q1 FY25, indicating operational improvements and increased capacity.
• Cash provided by operating activities slightly increased to $1.689 million from $1.657 million.
• The company plans to expand its diagnostic imaging centers with new scanner installations in Lynbrook, New York ($1.5 million) and another Long Island location ($400,000 scanner, $500,000 buildout) in fiscal year 2026.

Negatives

• Net income attributable to FONAR decreased by 27.8% to $2.264 million for the three months ended September 30, 2025, from $3.135 million in the prior year.
• Consolidated net income decreased by 33.25% to $2.670 million from $4.000 million year-over-year.
• Operating income declined by 30.7% to $3.194 million from $4.606 million in the same period last year.
• Total costs and expenses increased by 12.2% to $22.849 million, significantly outpacing the 4.3% revenue growth.
• Selling, general and administrative expenses increased substantially to $6.813 million from $5.130 million, partly due to take-private transaction expenses, IT/cybersecurity improvements, and a prior year expense accrual adjustment.
• The Manufacturing and Servicing of Medical Equipment segment's operating loss increased to $(1.204) million from $(1.043) million.
• The Management of Diagnostic Imaging Centers segment's operating income decreased to $4.398 million from $5.649 million, despite revenue growth, due to increased costs.
• Basic Net Income Per Common Share Available to Common Stockholders decreased to $0.34 from $0.47.
• Cash and cash equivalents decreased from $56.334 million at June 30, 2025, to $54.276 million at September 30, 2025.
• The stock repurchase plan was suspended due to the pending take-private offer.

Risks

• Uncertainty regarding the proposed non-binding take-private acquisition by a group led by the CEO and COO, with no assurance of completion and significant associated costs.
• Negative impact of the federal government shutdown (effective October 1, 2025) on claims processing time and reimbursement delays from the Center for Medicare Services (CMS).
• Reduced reimbursement rates from Medicare, other government programs, and private insurance companies for diagnostic imaging services, which are difficult to offset due to inflation in material and labor costs.
• Inflation drastically increasing costs for materials and labor, making organic growth more difficult and threatening the profitability of current operations and future expansion.
• Cybersecurity threats, including breaches, ransomware attacks, and denial-of-service attacks, which could disrupt operations, incur significant response costs, and potentially exceed cybersecurity liability insurance coverage.
• A material weakness in internal controls over information technology general controls (logical access management) identified as of June 30, 2025, and continuing as of September 30, 2025, which could lead to material misstatements.
• Dependence on referrals from unaffiliated physicians and third parties; a reduction in referrals would decrease scan volumes, net revenue, and operating margins.
• Negative impact from current and future changes in Florida Insurance Law, such as the Tort Reform Act (House Bill 837) and potential repeal of no-fault insurance, leading to unpaid bills, higher administrative costs, lower volume, and payment delays.
• High competition in the diagnostic imaging services market, particularly in Florida, which, coupled with recent Tort Reform, creates a challenging landscape and may deter future expansion.
• Pressure to control healthcare costs from managed care organizations, potentially impacting utilization, pricing, and reimbursement rates for services.
• Eligibility changes to insurance programs, leading to a shift towards uninsured or government program patients, resulting in reduced reimbursement rates or increased uncollectible receivables.
• Reduced demand for MRI scanners due to lower reimbursement rates, leading to lower sales volumes, reduced economies of scale, and consequently, lower profit margins.
• Competition from scanner manufacturers with significantly greater financial resources and production capacity, such as General Electric, Siemens, Hitachi, and Phillips.
• Adverse changes in general domestic and global economic conditions, including tariffs, recessions, credit market disruptions, and military conflicts, which could affect workforce, liquidity, financial condition, and profitability.

Future Outlook

The company is committed to improving operating results and addressing challenges from legislative and regulatory requirements. It plans to continue improving and expanding MRI facilities, increasing scan volumes, enhancing equipment service, and delivering innovative equipment. Material capital expenditures are planned for fiscal year 2026, including a new high-field scanner in Lynbrook, New York, and an additional location on Long Island. The company believes existing cash balances, internal cash generation, and potential additional financing are sufficient for operations for at least the next twelve months. However, the future effects of healthcare legislation, tariffs, reimbursement rates, public health conditions, and the general economic climate are uncertain and could adversely impact business operations.

Management Comments

• Management believes that its business plan has been responsible for its profitability in the past ten consecutive fiscal years and the first three months of fiscal 2026.
• Management believes its capital resources will be adequate to support operations through a year from the date of filing.
• Management is seeking to promote wider market recognition of FONAR's scanner products and to increase demand for Upright scanning at the facilities HMCA owns or manages.
• Management believes, based in part on the advice of counsel, that the ultimate resolution of legal proceedings will not have a material adverse effect on the company's consolidated financial position, results of operations, or cash flows.
• Management has identified and is implementing steps to remediate the material weaknesses in internal controls, with efforts ongoing.

Industry Context

The diagnostic imaging industry faces significant headwinds, including reduced reimbursement rates from Medicare, other government programs, and private insurers, which are impacting profitability across the sector. Inflation in material and labor costs further exacerbates these pressures, making it challenging for companies like FONAR to maintain margins and fund expansion. The market for MRI scanner products is depressed due to economic uncertainty and lower reimbursement rates. The industry is also increasingly vulnerable to cybersecurity threats, necessitating significant investment in IT security. Legislative changes, such as Florida's Tort Reform Act, introduce additional regulatory complexities and financial risks for operators in specific regions. The ongoing federal government shutdown poses an immediate risk of slower claims processing and reimbursement delays, affecting cash flow for healthcare providers.

Comparison to Industry Standards

• The filing notes that Medicare reimbursement rates for MRI scans continue to see year-over-year reductions, which is a broader industry trend affecting all providers, not unique to HMCA or its clients.
• The company acknowledges that many competing scanner manufacturers, such as General Electric, Siemens, Hitachi, and Phillips, have significantly greater financial resources and production capacity, highlighting a competitive disadvantage in the manufacturing segment, despite FONAR's unique Stand-Up MRI technology.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to legal proceedings and claims arising from the ordinary course of its business, including personal injury, customer contract, and employment claims, which are generally handled by insurance carriers.
• Management believes the aggregate liability from such actions will not have a material adverse effect on the consolidated financial position or results of operations.
• No material changes in litigation were reported from the Form 10-K for the fiscal year ended June 30, 2025.

Related Party Transactions

• Tallahassee Magnetic Resonance Imaging, Inc., Stand Up MRI of Boca Raton, Inc., and Stand Up MRI & Diagnostic Center, Inc. (related medical practices) cross-guaranteed all management fees payable to the Company. Net revenues owed to the Company from these practices were $10.027 million as of September 30, 2025, up from $9.748 million at June 30, 2025.
• Bensonhurst MRI Limited Partnership, in which the CEO and President holds an interest, has agreements for service and maintenance of two MRI scanners. The Company recorded $45,000 in service and repair fees from Bensonhurst for the three months ended September 30, 2025 and 2024. Additionally, Bensonhurst was charged $189,000 (2025) and $182,000 (2024) for reimbursable salaries and marketing expenses.
• Integrity Healthcare Management, LLC, owned by the CEO and President, holds a 7.1% interest in HMCA's Class A membership and receives distributions from the Company.
• Radian Healthcare Management, LLC, owned by the son-in-law of the CEO and President, provided personnel recruitment services to the Company for approximately $61,000 for the three months ended September 30, 2025, and $86,000 for the same period in 2024.
• Magnetic Resonance Management, LLC (MRM), owned by the CEO and President, purchased an MRI scanner from the Company for $577,000 via a promissory note (9% interest, due December 2028). The Company recorded $12,000 (2025) and $13,000 (2024) in investment income from this note, with an option to re-take possession of the scanner in lieu of payment.

Stakeholder Impact

• **Shareholders:** The non-binding take-private proposal introduces significant uncertainty regarding the future of their investment and the potential for delisting from NASDAQ. The decline in net income and EPS may negatively impact shareholder value. The suspension of the stock repurchase plan removes a potential source of demand for shares.
• **Employees:** The company's commitment to improving IT systems and expanding facilities could indicate job stability or growth in certain areas, but overall financial performance and cost control measures might create pressure.
• **Customers:** Increased scan volumes and planned equipment expansions suggest continued or improved access to diagnostic imaging services. However, reduced reimbursement rates and potential delays from government shutdowns could indirectly affect service providers and their ability to invest.
• **Suppliers:** Increased capital expenditures for new scanners and facility buildouts indicate continued demand for equipment and construction services. However, inflation and cost control measures could put pressure on pricing.
• **Creditors:** The company's existing cash balances and internal cash generation are believed to be sufficient for the next twelve months, suggesting stable creditworthiness in the short term, but declining profitability and significant risks warrant monitoring.

Next Steps

• The Special Committee of independent directors will continue to consider and negotiate the non-binding take-private proposal.
• The company will continue remediation efforts for the material weakness in internal controls over financial reporting, including enhancing risk assessment, implementing new user authentication procedures, and new monitoring controls.
• Complete the installation of an additional high-field scanner in Lynbrook, New York, in the second quarter of fiscal 2026.
• Open an additional diagnostic imaging center location on Long Island, New York, before the end of the fiscal year.
• Management will continue to evaluate the impact of the new tax law (One Big Beautiful Act) on its financial condition and results of operations.
• Monitor and adapt to potential changes in CMS payment policies and reimbursement rates due to the federal government shutdown.

Key Dates

Recommendation

The company's Q1 FY26 results show a concerning decline in profitability, with operating income down over 30% and net income down nearly 28%, despite a modest revenue increase. This is primarily driven by significantly higher costs and expenses. While operational improvements like increased scan volumes and planned expansions are positive, they are overshadowed by substantial risks including the uncertainty of the take-private proposal, the impact of a federal government shutdown on reimbursements, persistent inflation, reduced industry reimbursement rates, and an identified material weakness in internal controls. The take-private offer, while potentially offering a premium, also introduces significant uncertainty and has led to the suspension of the stock repurchase program. Given the mixed signals, declining profitability, and numerous external and internal risks, a 'hold' recommendation is appropriate. Investors should await further clarity on the take-private transaction and evidence of successful remediation of internal control weaknesses and mitigation of external pressures before making further investment decisions.

Keywords

MRI, Diagnostic Imaging, Healthcare Management, SEC Filing, 10-Q, Quarterly Report, Take-Private, Corporate Governance, Financial Performance, Reimbursement Rates, Inflation, Cybersecurity, Internal Controls, Medical Equipment, FONAR